Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 05  •  03:21PM ET
17.98
Dollar change
+0.55
Percentage change
3.17
%
IndexRUT P/E- EPS (ttm)-1.05 Insider Own20.43% Shs Outstand87.47M Perf Week124.23%
Market Cap1.57B Forward P/E- EPS next Y-1.27 Insider Trans0.26% Shs Float69.63M Perf Month125.07%
Enterprise Value1.26B PEG- EPS next Q-0.30 Inst Own83.32% Short Float14.88% Perf Quarter218.85%
Income-91.75M P/S- EPS this Y0.03% Inst Trans-3.69% Short Ratio5.13 Perf Half Y494.48%
Sales0.00M P/B5.15 EPS next Y-13.86% ROA-33.28% Short Interest10.36M Perf YTD224.60%
Book/sh3.49 P/C4.99 EPS next 5Y-7.87% ROE-35.02% 52W High18.75 -4.09% Perf Year159.12%
Cash/sh3.60 P/FCF- EPS past 3/5Y17.43% 16.38% ROIC-29.99% 52W Low1.87 864.24% Perf 3Y160.25%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility14.02% 9.30% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM20.37% Oper. Margin- ATR (14)1.42 Perf 10Y-
Dividend Ex-Date- Quick Ratio24.70 Sales Y/Y TTM- Profit Margin- RSI (14)87.53 Recom1.09
Dividend Gr. 3/5Y- - Current Ratio24.70 EPS Q/Q13.85% SMA2090.16% Beta-0.23 Target Price24.50
Payout- Debt/Eq0.00 Sales Q/Q- SMA50116.20% Rel Volume1.83 Prev Close17.43
Employees59 LT Debt/Eq0.00 EarningsAug 05 AMC SMA200250.97% Avg Volume2.02M Price17.98
IPOFeb 05, 2021 Option/ShortYes / No EPS/Sales Surpr.10.44% - Trades Volume3,352,737 Change3.17%
Date Action Analyst Rating Change Price Target Change
Nov-04-25Upgrade H.C. Wainwright Neutral → Buy $20
Nov-03-25Upgrade William Blair Mkt Perform → Outperform
Oct-15-25Initiated Truist Buy $20
Sep-17-25Initiated Barclays Overweight $15
Sep-04-25Resumed H.C. Wainwright Neutral
Feb-28-25Initiated William Blair Mkt Perform
Oct-31-24Initiated Oppenheimer Outperform $82
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
May-31-23Initiated ROTH MKM Buy $23
Nov-04-25 04:05PM
Nov-03-25 09:05AM
Oct-24-25 04:58AM
Oct-21-25 04:05PM
Oct-02-25 04:05PM
10:45AM Loading…
Sep-21-25 10:45AM
Aug-21-25 04:05PM
Aug-07-25 09:55AM
Aug-05-25 04:05PM
Aug-04-25 04:05PM
Jun-23-25 04:07PM
May-29-25 04:05PM
May-14-25 09:30AM
May-09-25 07:54AM
May-08-25 04:05PM
04:05PM Loading…
May-02-25 04:05PM
Apr-30-25 04:05PM
Apr-26-25 08:50AM
Apr-07-25 09:35AM
Apr-03-25 09:35AM
Apr-02-25 04:05PM
Mar-26-25 12:00PM
Mar-20-25 04:05PM
Mar-09-25 10:03AM
Feb-26-25 04:05PM
Feb-25-25 08:05AM
03:00AM
Feb-24-25 04:05PM
Feb-20-25 04:05PM
Feb-05-25 04:05PM
04:05PM Loading…
Feb-03-25 04:05PM
Jan-08-25 04:05PM
Jan-02-25 04:05PM
Dec-16-24 01:10PM
Dec-03-24 07:00AM
Dec-02-24 04:05PM
Nov-18-24 04:05PM
Nov-12-24 04:05PM
Nov-06-24 04:05PM
Oct-07-24 04:05PM
Sep-24-24 03:22AM
Sep-18-24 10:07AM
Sep-17-24 01:30AM
Sep-15-24 07:21AM
06:09AM
Sep-14-24 10:12AM
Sep-12-24 07:00PM
Sep-10-24 10:50PM
04:52AM
Sep-09-24 04:01PM
09:58AM
09:24AM
08:06AM
07:05AM
Aug-28-24 09:55AM
Aug-05-24 09:56PM
04:05PM
Aug-02-24 01:54PM
Aug-01-24 04:05PM
Jul-29-24 04:05PM
Jul-26-24 06:40PM
Jul-20-24 09:30AM
Jun-21-24 06:30PM
Jun-19-24 01:27PM
Jun-04-24 09:55AM
Jun-03-24 04:10PM
May-30-24 08:05AM
May-17-24 04:05PM
May-13-24 01:53PM
09:32AM
08:05AM
May-08-24 04:05PM
May-07-24 04:05PM
May-03-24 04:05PM
Apr-29-24 04:05PM
Apr-10-24 04:05PM
Mar-14-24 04:05PM
Mar-11-24 04:05PM
Mar-07-24 04:05PM
Feb-27-24 04:05PM
Feb-07-24 04:05PM
08:05AM
Feb-02-24 04:05PM
Jan-04-24 04:05PM
Jan-03-24 04:05PM
Nov-29-23 04:05PM
Nov-27-23 04:05PM
Nov-14-23 12:16PM
08:05AM
Nov-13-23 08:05AM
Nov-09-23 08:05AM
Nov-03-23 04:05PM
Nov-02-23 04:05PM
Oct-19-23 04:05PM
Oct-16-23 08:05AM
Oct-03-23 04:05PM
Sep-06-23 04:05PM
Sep-05-23 04:05PM
Aug-08-23 04:15PM
04:05PM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JILL QUIGLEYDirectorNov 04 '25Proposed Sale14.0324,520344,016Nov 04 04:32 PM
Kuriakose EmilChief Medical OfficerOct 01 '25Sale7.859447,40751,520Oct 02 07:24 PM
Kuriakose EmilChief Medical OfficerJul 01 '25Sale4.278533,64052,464Jul 03 02:55 PM
Gengos AndrewChief Financial OfficerJun 27 '25Buy3.9310,00039,28325,000Jun 30 05:38 PM
Burroughs Amy L.Chief Executive OfficerJun 25 '25Buy3.8723,31490,23047,083Jun 25 06:08 PM
Gengos AndrewChief Financial OfficerJun 13 '25Buy3.7310,00037,35010,000Jun 16 06:05 PM
Gengos AndrewChief Financial OfficerJun 16 '25Buy3.955,00019,73215,000Jun 16 06:05 PM
Kuriakose EmilChief Medical OfficerApr 01 '25Sale2.499522,36653,317Apr 02 06:48 PM
Jung Melita SunChief Business OfficerNov 30 '24Buy5.112,25011,4982,250Feb 03 07:28 PM
Burroughs Amy L.Chief Executive OfficerNov 30 '24Buy5.115102,60619,609Feb 03 07:25 PM
Kuriakose EmilChief Medical OfficerJan 02 '25Sale5.714,48125,60754,269Jan 06 07:30 PM
Vignola Mark J.Chief Financial OfficerJan 06 '25Sale5.809,05952,50074,752Jan 06 07:30 PM
Vignola Mark J.Chief Financial OfficerJan 02 '25Sale5.728,12946,52483,811Jan 06 07:30 PM
Quigley Jill M.DirectorJan 06 '25Sale5.798,76050,7580Jan 06 07:30 PM
Quigley Jill M.DirectorJan 02 '25Sale5.726,24035,7028,760Jan 06 07:30 PM
MARK J VIGNOLAOfficerJan 06 '25Proposed Sale5.759,05952,089Jan 06 04:29 PM
JILL QUIGLEYDirectorJan 06 '25Proposed Sale5.758,76050,370Jan 06 04:29 PM
Burroughs Amy L.Chief Executive OfficerDec 05 '24Buy7.1515,450110,46819,099Dec 09 06:04 PM